

Insight to BVS From Intracoronary Imaging




Fernando Alfonso MD, PhD, FESC

**Cardiac Department.
Hospital Universitario de La Princesa.
Insituto de Investigación Sanitaria IIS-IP
Universidad Autónoma de Madrid.
Madrid. Spain.**

December 5-6, 2014


Grand Intercontinental Seoul Parnas, Seoul, Korea

BVS Imaging Follow-up





Intracoronary Optical Coherence Tomography and Histology at 1 Month and 2, 3, and 4 Years After Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model

Classification with OCT



Classification with Histology



1 month

6 months

18 months

24 months




30 months

36 months


42 months

Dynamic Vessel Wall Changes up to 24 Months

IVUS



IVUS-VH




	BL (n=26)	6 mo (n=26)	24 mo (n=26)
Dense calcium area, %	31.2±13.3	29.8±10.5	27.6±8.0
Necrotic core area, %	30.8±8.0	30.6±6.0	31.1±4.5
IVUS Echogenicity (n=25)		(n=25)	(n=25)
% Hyperechogenicity	25.3±10.4	20.4±8.9	13.8±6.7


Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

(OCT). Between one and three years, late luminal loss remained unchanged (6 months: 0.19 mm, 1 year: 0.27 mm, 2 years: 0.27 mm, 3 years: 0.29 mm) and the in-segment angiographic restenosis rate for the entire cohort B (n=101) at three years was 6%. On IVUS, mean lumen, scaffold, plaque and vessel area showed enlargement up to two years. Mean lumen and scaffold area remained stable between two and three years whereas significant reduction in plaque behind the struts occurred with a trend toward adaptive restrictive remodelling of EEM. Hyperechogenicity of the vessel wall, a surrogate of the bioresorption process, decreased from 23.1% to 10.4% with a reduction of radiofrequency backscattering for dense calcium and necrotic core. At three years, the count of strut cores detected on OCT increased significantly, probably reflecting the dismantling of the scaffold; 98% of struts were covered. In the entire cohort B (n=101), the three-year major adverse cardiac event rate was 10.0% without any scaffold thrombosis.


Absence of «Delayed» Late Loss



Vasodilation Response




Late increase in Lumen Area. Late decrease in Plaque Area




BVS

IVUS





OCT



Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention

(63%) type A and seven (37%) type B or C. Of 29 scaffolds analysed, 28% required further intervention after OCT review, three (37.5%) due to scaffold malapposition and five (62.5%) due to scaffold underexpansion.






Malapposition


BVS Fracture

Avoid post-dilation with a balloon diameter > 0.5 mm nominal diameter


BVS for ISR: OCT Findings




OCT Guidance of BVS for ISR




OCT Guidance of BVS for ISR






OCT Guidance of BVS for ISR: Suboptimal Results?




BVS After Rotational Atherectomy in Heavily Calcified Lesions




86-year-old man with inferior STEMI




BVS in STEMI




**Ruptured Fibrous Cap
Complex Fibroatheroma**



**Cholesterol Crystals
Necrotic Core**




Thrombus



Red thrombus but also a ruptured fibrous cap underlying a complex fibroatheroma, including cholesterol crystals and foam cells and a large necrotic core

Can the Scaffold «Cap» the Plaque ?

Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?



Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data





In Absorb BVS, neointima tissue continued to develop at midterm follow-up ($2.17 \pm 0.48 \text{ mm}^2$ vs. $1.38 \pm 0.52 \text{ mm}^2$, $p < 0.0001$) and covered the underlying tissues without compromising the luminal dimensions ($5.93 \pm 1.49 \text{ mm}^2$ vs. $6.14 \pm 1.49 \text{ mm}^2$, $p = 0.571$) as it was accommodated by the expanded scaffold ($8.28 \pm 1.74 \text{ mm}^2$ vs. $7.67 \pm 1.28 \text{ mm}^2$, $p < 0.0001$).

Neointimal tissue develops following either Absorb BVS or BMS implantation and shields lipid tissues. The neointimal response in the BMS causes a higher reduction of luminal dimensions compared to the Absorb BVS. Thus, Absorb BVS may have a value in the invasive re-capping of high-risk plaques.


Neointimal Cap Seals Underlying Plaque

BVS


BMS



Anterior STEMI. Ambiguous Lesion in the RCA (Non-Culprit)



Anterior STEMI. Ruptured Plaque With Red Thrombus in a Non-Culprit Vessel



Insight to BVS From Intracoronary Imaging

- **Imaging has been instrumental to confirm the value of BVS in simple lesions**
- **Imaging appears very attractive to guide and optimize complex coronary interventions**
- **Imaging will be able to assess final healing pattern after BVS implantation**